Tag: CXM

Latest articles

Roche's Hemlibra® available on NHS

NHS England makes Roche’s Hemlibra® available on NHS

NHS England has made Roche's Hemlibra® available on NHS. It is to fund the “life-changing treatment” for thousands of people with severe Haemophilia, which...
Responding to the UK Prime Minister's committment to improving declining vaccination rates, the ABPI said tackling vaccine hesitancy should be a priority.

ABPI says prioritise ‘vaccine hesitancy’ as UK loses measles-free status

Responding to the news that the UK Prime Minister has committed to improving declining vaccination rates, Dr Sheuli Porkess, Executive Director at the ABPI,...
AbbVie receives FDA approval of RINVOQ™

AbbVie receives FDA approval of RINVOQ™

The U.S. Food and Drug Administration (FDA) has approved AbbVie's RINVOQ™ (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for the treatment...

Popular articles

Roche's Hemlibra® available on NHS

NHS England makes Roche’s Hemlibra® available on NHS

NHS England has made Roche's Hemlibra® available on NHS. It is to fund the “life-changing treatment” for thousands of people with severe Haemophilia, which...
Building blocks: Building trust with sales representatives

Building trust in health with sales representatives

Paul Terry explores how the sales representative is best placed to build trust with the health sector, and how industry needs to adapt to...
The Cabinet Office and Department of Health and Social Care have published their Prevention Green Paper, Advancing our health: prevention in the 2020s. It sets out plans to tackle the causes of preventable ill health in England.

Prevention Green Paper published – Advancing our health: prevention in the 2020s

The Cabinet Office and Department of Health and Social Care have published their Prevention Green Paper, Advancing our health: prevention in the 2020s. It...
pain relief patch released by nurofen

Nurofen launches a 24 hour ibuprofen pain relief patch

Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen.  Despite body pain being among the most commonly...
AbbVie receives FDA approval of RINVOQ™

AbbVie receives FDA approval of RINVOQ™

The U.S. Food and Drug Administration (FDA) has approved AbbVie's RINVOQ™ (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for the treatment...

Subscribe

Sign up to receive your free UK subscription to Pf Magazine and our digital newsletters, for all the essential headlines, Jobs of the Week, and thought-provoking features.

Claim my free subscription